出租车司机

China's pharmaceutical industry sees accelerated innovation breakthroughs in H1_我的网站

一 |     8月24日凌晨，《主角》“楚嘉禾”扮演者韩沛颖开启深夜直播，情绪失控连发多项控诉，接连引爆网络热搜，引发全网热议。    (ECNS) -- China's pharmaceutical industry accelerated innovation in the first half of this year, with domestic companies steadily improving their R&D capabilities and growth momentum continuing to strengthen, data showed.    China's first broad-spectrum targeted anticancer drug entered clinical use at major hospitals across the country this year. It took only eight months to go from submission to market approval.    A total of 38 innovative drugs were approved for marketing in China in the first half, of which 31 were developed domestically, more than 80% of the total. Eleven drugs featuring new targets or new mechanisms were all developed independently by domestic companies, producing a number of world-first innovations. By the end of 2025, China had 4,751 innovative drugs under development, one-third of the global total and the largest pipeline of any country.    Behind this concentration of results lies a steadily strengthening industrial base. China has a complete pharmaceutical supply chain. It is not only the world's largest producer of active pharmaceutical ingredients but has also built a production system covering every pharmaceutical category.    This year, digital, intelligent, and green technologies have driven the industry's transformation and upgrading.     At a biopharmaceutical company in Shanxi Province, a newly built AI-powered bio-computing center can identify the structures of millions of protein functional domains in a short time, screening out ineffective molecules directly.    To date, China has supported 21 pharmaceutical firms in building excellent-level smart factories and has cultivated more than 300 green factories. In the first half, the added value of pharmaceutical enterprises above the designated scale grew 6.4% year on year, and exports held strong.    The world's first chemotherapy-sparing drug for gastric cancer, launched this year, had already earned overseas revenue through licensing deals before it reached the market, and is now exported to multiple countries and regions.    In the first half, the total value of China's innovative drug out-licensing deals reached $110 billion, the industry's export delivery value grew 9% year on year, and high-value-added products made up nearly 20% of the total.        (By Tang Yuxian)                    。直播中，韩沛颖重点控诉自己在剧中“杨门女将”重头戏遭大量删减，多次质问删减缘由，直言“我被欺负了还不能讲吗”，并称将公开剧本、录屏维权。她同时澄清拍戏全程仅用一位替身，无网传“假脑袋”情况，还为遭网暴的替身演员发声维权。此外，她曝光自身经纪乱象，吐槽经纪人将其演艺工作当作副业，导致自己长期无商务合约、不了解合同细节，坦言长期遭遇职场不公，情绪几度崩溃失控。此次风波还牵扯王晓晨、刘浩存两位艺人。针对王晓晨此前夸赞刘浩存“被泼菜戏份拍一下午”的敬业言论，韩沛颖解读为暗讽自己演技差、频繁返工，转发视频质问“请问几件衣服？”，并多次隔空喊话、要求王晓晨公开道歉，目前对方暂无任何回应。整场直播最大争议为韩沛颖的矛盾言论。

二 | 她曾脱口发表影射刘浩存的不当言论，引发舆论哗然，随后又火速改口否认，声称尊重每一位演员，前后相悖的表述遭到网友诟病，被指无依据恶意揣测、刻意制造争议。舆论发酵后，大批网友质疑其言行不当，刘浩存粉丝喊话其公开道歉，并表示将依法维权。韩沛颖随后发文撇清关系，称自身相关热搜与其他艺人无关，但未对争议言论作出解释与致歉。目前，该事件仍在持续发酵中，各方暂无最新官方回应。

三 |

Current article:http://59z8kf1.yaoyaotoutuanmieshaideizun.buzz/list_mc9ztay/6q7.html

Published on:04:46:59